TR200002733T2 - Demir-eksikliğinin önlenmesi veya tedavisi için bir tedavi edici bileşimde bir bileşen olarak kullanım için bir demir-dekstran bileşiği ve üretilmesi için bir işlem - Google Patents

Demir-eksikliğinin önlenmesi veya tedavisi için bir tedavi edici bileşimde bir bileşen olarak kullanım için bir demir-dekstran bileşiği ve üretilmesi için bir işlem

Info

Publication number
TR200002733T2
TR200002733T2 TR2000/02733T TR200002733T TR200002733T2 TR 200002733 T2 TR200002733 T2 TR 200002733T2 TR 2000/02733 T TR2000/02733 T TR 2000/02733T TR 200002733 T TR200002733 T TR 200002733T TR 200002733 T2 TR200002733 T2 TR 200002733T2
Authority
TR
Turkey
Prior art keywords
dextran
iron
daltons
molecular weight
treatment
Prior art date
Application number
TR2000/02733T
Other languages
English (en)
Inventor
Berg Andreasen Hans
Christensen Lars
Original Assignee
Pharmacosmos Holding A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8093321&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200002733(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacosmos Holding A/S filed Critical Pharmacosmos Holding A/S
Publication of TR200002733T2 publication Critical patent/TR200002733T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Demir-eksikligi anemisinin paranterel tedavisi için bir demir-dekstran bilesigi 700 ila 1,400 Dalton arasinda, tercihen yaklasik olarak 1,000 Dalton olan bir ortalama agirlikli molekül agirligina (Mw), 400, ila 1,400 Dalyon bir ortalama molekül agirligi sayisina (Mn) sahip hidrojene dekstran içerir ve burada dekstranin agirlikça %90'i 2,700 Dalton'dan daha az molekül agirligina sahiptir ve en yüksek molekül agirligina sahip dekstran fraksiyonun agirlikça %10' nunun Mw degeri 3,200 Dalton'un altindadir, bahsedilen hidrojene dekstran, demirli oksihidroksit ile dengeli birlesiminde, 340 ila 800 Dalton arasindaki bir kesme degerine sahip membran islemleriyle saflastirmaya tabi tutulur. Bilesik, yaklasik olarak 2,700 Dalton'dan daha yüksek molekül agirligina sahip dekstranlari elimine etmek için ve bahsedilen dekstranin varliginda demirli hidroksiti çöktürmeden önce hidrojene dekstrandan yaklasik 340 Dalton'dan daha düsük molekül agirlikli sakkaritlerin uzaklastirilmasi için DEVAMI VAR
TR2000/02733T 1998-03-25 1999-03-24 Demir-eksikliğinin önlenmesi veya tedavisi için bir tedavi edici bileşimde bir bileşen olarak kullanım için bir demir-dekstran bileşiği ve üretilmesi için bir işlem TR200002733T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK199800420A DK172860B1 (da) 1998-03-25 1998-03-25 Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernman

Publications (1)

Publication Number Publication Date
TR200002733T2 true TR200002733T2 (tr) 2000-12-21

Family

ID=8093321

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/02733T TR200002733T2 (tr) 1998-03-25 1999-03-24 Demir-eksikliğinin önlenmesi veya tedavisi için bir tedavi edici bileşimde bir bileşen olarak kullanım için bir demir-dekstran bileşiği ve üretilmesi için bir işlem

Country Status (28)

Country Link
US (1) US6291440B1 (tr)
EP (1) EP1066056B2 (tr)
JP (1) JP4558198B2 (tr)
KR (1) KR100612071B1 (tr)
CN (1) CN1147322C (tr)
AR (1) AR015738A1 (tr)
AT (1) ATE220560T1 (tr)
AU (1) AU740432B2 (tr)
BR (1) BRPI9908914B8 (tr)
CA (1) CA2322633C (tr)
CZ (1) CZ300823B6 (tr)
DE (1) DE69902154T3 (tr)
DK (2) DK172860B1 (tr)
EA (1) EA003427B1 (tr)
ES (1) ES2180279T5 (tr)
HK (1) HK1033426A1 (tr)
HU (1) HU228483B1 (tr)
ID (1) ID26778A (tr)
NO (1) NO329591B1 (tr)
NZ (1) NZ505983A (tr)
PL (1) PL195582B1 (tr)
PT (1) PT1066056E (tr)
SI (1) SI1066056T2 (tr)
SK (1) SK284499B6 (tr)
TR (1) TR200002733T2 (tr)
UA (1) UA70939C2 (tr)
WO (1) WO1999048533A1 (tr)
ZA (1) ZA200004016B (tr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173138B1 (da) * 1998-11-20 2000-02-07 Pharmacosmos Holding As Fremgangsmåde til fremstilling af en jerndextranforbindelse, jerndextranforbindelse fremstillet efter fremgangsmåden, farma
DK1169062T3 (da) * 1999-04-09 2010-01-25 Amag Pharmaceuticals Inc Varmestabile overtrukne kolloide jernoxider
US7871597B2 (en) 1999-04-09 2011-01-18 Amag Pharmaceuticals, Inc. Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
KR20020003344A (ko) * 2001-12-17 2002-01-12 유형선 철분 보급제 경구 투여 제제 조성물
CN1309741C (zh) * 2002-04-09 2007-04-11 法玛科思莫斯控股有限公司 用于治疗缺铁性贫血的铁糊精化合物
DE10249552A1 (de) 2002-10-23 2004-05-13 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
US20060116349A1 (en) * 2003-03-14 2006-06-01 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron for the treatment of restless leg syndrome
DE102004031181A1 (de) * 2004-06-28 2006-01-19 Vifor (International) Ag Phosphatadsorbens
ITMO20050056A1 (it) * 2005-03-15 2006-09-16 Biofer Spa Processo per la preparazione di complessi del ferro trivalente con zuccheri mono-, di- e polisaccaridi.
EP1757299A1 (de) 2005-08-25 2007-02-28 Vifor (International) Ag Eisen(III)-Komplexverbindungen zur Behandlung von Eisenmangel-Zuständen bei Patienten mit chronisch-entzündlicher Darmerkrankung
CN101365458B (zh) 2006-01-06 2012-09-05 卢特波尔德药品公司 用于铁给药的方法和组合物
EP1947120A1 (de) * 2007-01-19 2008-07-23 Vifor (International) Ag Eisen-Kohlenhydrat-Komplex-Verbindungen
EP1997833A1 (de) * 2007-05-29 2008-12-03 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydratderivat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
CN101585887B (zh) * 2008-05-22 2011-12-14 中国科学院过程工程研究所 应用纳滤技术对右旋糖酐铁络合物水溶液进行脱盐和浓缩的方法
NZ595597A (en) * 2009-03-25 2013-05-31 Pharmacosmos Holding As A stable iron oligosaccharide compound
CN101967205B (zh) * 2010-10-12 2013-04-17 滨州学院 一种β-葡聚糖铁复合物及其制备方法
EP2537866A1 (en) * 2011-06-21 2012-12-26 Serumwerk Bernburg AG Hydroxyethyl starch derivatives, method for manufacturing the same and therapeutical uses thereof
PL398814A1 (pl) 2012-04-16 2013-10-28 Uniwersytet Jagiellonski Zastosowanie pochodnych dekstranu do przeciwdzialania lub leczenia niedokrwistosci
EP3157516A4 (en) 2014-06-22 2017-12-13 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
ES2743223T3 (es) * 2014-10-27 2020-02-18 Pharmacosmos Holding As Tratamiento o prevención de la anemia en mamíferos no humanos gestantes y crías
BR112020004357A2 (pt) * 2017-09-11 2020-09-08 Pharmacosmos Holding A/S compostos de complexo de ferro para uso terapêutico
CN109646454A (zh) * 2018-12-29 2019-04-19 博瑞生物医药（苏州）股份有限公司 异麦芽糖酐铁1000的制备方法
CN110183548B (zh) * 2019-06-28 2021-05-18 瑞普（天津）生物药业有限公司 一种低分子葡聚糖铁的制备方法及其应用
JP2024529536A (ja) 2021-08-03 2024-08-06 ファーマコスモス ホールディング エー／エス コンパニオンアニマルの鉄欠乏症の治療における皮下使用のための鉄錯体化合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK117730A (tr)
USRE24642E (en) 1959-04-28 Therapeutic preparations of iron
US2885393A (en) 1956-02-24 1959-05-05 R K Laros Company Dextran-iron complex and process for making same
US3093545A (en) 1960-08-29 1963-06-11 Armour Pharma Therapeutic iron-dextran preparations
US3234209A (en) * 1963-09-13 1966-02-08 Chemicals Inc Process for making iron hydrogenated dextran
DE1293144B (de) * 1964-11-04 1969-04-24 Hausmann Ag Labor Verfahren zur Herstellung von Komplexverbindungen des Eisens mit Sorbit, Gluconsaeure und einem Oligosaccharid
GB1183940A (en) 1966-10-22 1970-03-11 Fisons Pharmaceuticals Ltd Ferric Hydroxide Complexes
GB1200902A (en) 1967-05-13 1970-08-05 Fisons Pharmaceuticals Ltd Iron-dextran complexes
CH507993A (de) 1967-07-13 1971-05-31 Kutnowskie Zakl Farma Verfahren zur Herstellung von Eisen(III)-komplexverbindungen mit hydriertem Dextran
DK129353B (da) 1968-04-29 1974-09-30 Fisons Pharmaceuticals Ltd Analogifremgangsmåde til fremstilling af et ferrihydroxid-dextranderivatkompleks eller en opløsning deraf.
US3697502A (en) 1969-11-03 1972-10-10 Christensen Henry M Method of making iron dextran-preparations
GB1562913A (en) * 1976-06-16 1980-03-19 Fisons Ltd Fractionating fluid mixtures of dextrans
DE3422249A1 (de) * 1984-06-15 1985-12-19 Pfeifer & Langen, 5000 Köln Wasserloesliches eisendextran und verfahren zu seiner herstellung
US5102652A (en) 1986-07-03 1992-04-07 Advanced Magnetics Inc. Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
US4827945A (en) 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
IT1263831B (it) * 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
RU2093577C1 (ru) * 1993-11-04 1997-10-20 Государственный институт кровезаменителей и медицинских препаратов Способ получения декстрана
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
US5624668A (en) * 1995-09-29 1997-04-29 Luitpold Pharmaceuticals, Inc. Iron dextran formulations

Also Published As

Publication number Publication date
CZ20003535A3 (cs) 2001-04-11
ES2180279T3 (es) 2003-02-01
EP1066056B2 (en) 2008-12-10
KR100612071B1 (ko) 2006-08-11
UA70939C2 (uk) 2004-11-15
SK284499B6 (sk) 2005-05-05
CZ300823B6 (cs) 2009-08-19
ATE220560T1 (de) 2002-08-15
DK1066056T3 (da) 2002-10-14
CN1147322C (zh) 2004-04-28
DK42099A (da) 1999-08-16
JP2002507582A (ja) 2002-03-12
ES2180279T5 (es) 2009-05-05
EP1066056B1 (en) 2002-07-17
DE69902154T2 (de) 2003-03-06
ZA200004016B (en) 2001-07-25
HK1033426A1 (en) 2001-08-31
HU228483B1 (en) 2013-03-28
EA200000981A1 (ru) 2001-02-26
PL343164A1 (en) 2001-07-30
KR20010034641A (ko) 2001-04-25
CA2322633A1 (en) 1999-09-30
AU740432B2 (en) 2001-11-01
JP4558198B2 (ja) 2010-10-06
CN1293577A (zh) 2001-05-02
PT1066056E (pt) 2002-12-31
WO1999048533A1 (en) 1999-09-30
US6291440B1 (en) 2001-09-18
DK1066056T4 (da) 2009-04-14
NO20004151L (no) 2000-08-18
NO20004151D0 (no) 2000-08-18
EA003427B1 (ru) 2003-04-24
EP1066056A1 (en) 2001-01-10
CA2322633C (en) 2009-01-27
PL195582B1 (pl) 2007-10-31
HUP0101189A3 (en) 2003-12-29
ID26778A (id) 2001-02-08
BRPI9908914A (pt) 2000-11-21
DE69902154D1 (de) 2002-08-22
BRPI9908914B1 (pt) 2012-06-12
BRPI9908914B8 (pt) 2021-07-06
SI1066056T2 (sl) 2009-04-30
HUP0101189A2 (hu) 2001-08-28
AU2827399A (en) 1999-10-18
NO329591B1 (no) 2010-11-15
SK14092000A3 (sk) 2001-04-09
DE69902154T3 (de) 2009-07-09
SI1066056T1 (en) 2002-12-31
NZ505983A (en) 2002-11-26
DK172860B1 (da) 1999-08-16
AR015738A1 (es) 2001-05-16

Similar Documents

Publication Publication Date Title
TR200002733T2 (tr) Demir-eksikliğinin önlenmesi veya tedavisi için bir tedavi edici bileşimde bir bileşen olarak kullanım için bir demir-dekstran bileşiği ve üretilmesi için bir işlem
Lee et al. Effect of surface properties on the antithrombogenicity of silk fibroin/S-carboxymethyl kerateine blend films
Loaec et al. Chelating properties of bacterial exopolysaccharides from deep-sea hydrothermal vents
CA2007616A1 (en) Heparinic derivatives and process for their preparation
NZ315275A (en) Inhalant composition including ultra low mw heparins (ULMWH) to treat asthma
AU2619995A (en) New sulphonated polyesters and their use as antisoiling agents in detergent compositions for rinsing, softening and the treatment of textiles
CN1318452C (zh) 一种6－羧基甲壳素的制备方法
CA2203621A1 (en) Use of Hyaluronic Acid for the Treatment of Interstitial Cystitis
MXPA01008283A (es) Composiciones de polisacaridos y uso de las mismas.
CA2240711A1 (en) Low molecular weight structured polymers
AU652729B2 (en) Aqueous dispersions of cross-linked polymer microparticles
Giraux et al. Fucoidan, as heparin, induces tissue factor pathway inhibitor release from cultured human endothelial cells
HK1028251A1 (en) Oligosaccharide mixtures having antithrombotic activity
NO985103L (no) Detergentsammensetninger omfattende modifiserte polyaminpolymerer og cellulase-enzymer
EP0870863A3 (en) Method for finishing treatment of a fabric material
AU2001289689A1 (en) Partially branched polymers
Décout et al. Synthesis and catalytic activity of adenine containing polyamines
ES464960A1 (es) Procedimiento para la preparacion de ligantes termoendureci-bles para revestimientos depositables catodicamente.
AU5833694A (en) Oligosaccharides having biological activity and preparation of same from glycosaminoglycans
Song et al. Synthesis of biocompatible CS-g-CMS ion exchangers and their adsorption behavior for heavy metal ions
Fukatsu et al. Catalytic activity of the Cu (II)-wool complex on the oxidation of ascorbic acid
Okieimen et al. Grafting acrylonitrile and methyl methacrylate on holocellulosic materials
CN115233458B (zh) 一种提高白鸭绒蓬松度的加工工艺
Müller et al. Studies on the mechanism of PMN activation I. by dextran sulfates
Carson et al. Mechanism of potentiation of antithrombin III and heparin cofactor II inhibition by sulfated xylans